PeptideWellness
Take the quiz
§ By goal
§ Most read
Featured · field guide
The 2026 GLP-1 telehealth field guide.

Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.

Read the guide
§ The providers
Who sells what — and who to trust.

An independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.

View the provider overviewAll 17 reviews
§ Learn
The educational layer, in progress.

Primers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.

View all Learn articles
§ Interactive tools
60-second quiz PeptideMatch Start here Answer four questions, get a goal-matched protocol and provider. The record GLP-1 price history Every price change we have recorded, with the figure before and after it. Overview All tools The full tools page — quiz, the Index, its history, and how we build them. Method How we measure a price What counts as the price, where we read it, and how often it is re-checked.
Free to use Medically reviewed methodology How we build our tools
PeptideWellness Index
The GLP-1 Price Index

What compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.

See the full index
Whitepapers

Independent field reports.

Source-cited intelligence on compounded peptides and the regulatory landscape, written for prescribers and buyers. All three reports are still in production.

Back to the Pros zone
Editorial independence

Reports are produced independently. We don't accept payment from manufacturers, pharmacies, or clinics for inclusion, and nothing here is sponsored. Each report will carry its reviewer and its sources when it publishes; none of them is finished, so none is available to download yet.

The reports

In preparation.

Three field reports are in production, and each will be free to read when it's done. There's no signup to join in the meantime — everything that will go into them is published as it happens in News and Regulatory updates.

LM-8 · ~24 pages

State of Compounded Peptides 2026

Where 503A/503B supply stands after the 2025 delistings, compounded-GLP-1 pricing by channel, and what credentialed clinics are prescribing.

In preparation
LM-7 · ~20 pages

Peptide Regulatory Landscape 2026

FDA compounding rules, the 503A bulks list, salt-form issues, and the PCAC timeline — in one map.

In preparation
LM-9 · ~8 pages

Compounding Pharmacy Vetting Checklist

How to validate a 503A/503B compounder — accreditation, inspection record, and the red flags.

In preparation